Browser Not Supported.

IE users: please get the latest browser version at Microsoft Internet Explorer Home Page

if yot already have the latest browser version please verify that your browser settings is not in compatibility mode

Browser: unknown
Version: 0

EMBRYONIC DEVELOPMENT & STEM CELL COMPENDIUM
Content

Generation of vascular smooth muscle cells from human embryonic stem cells

This protocol describes the generation of coronary-like vascular smooth muscle cells (VSMCs) and cardiogenic progenitor cells from human embryonic stem cells (hESC). Differentiation into VSMCs is achieved in a 4-stage process. In the first and second stages, after 8 days in suspension culture, cells differentiate, in embryoid bodies (EBs), into primitive-streak and cardiac mesoderm-like cells, respectively. At the end of the third stage, the embryoid bodies contain a mixture of endothelial, cardiogenic, and smooth muscle progenitor cells. When EBs are disrupted and cells are cultured in low-density monolayer cultures for several passages, cells continue to express smooth muscle markers, whereas the expression of both cardiogenic and endothelial markers is reduced. The functional potential of the hESC-derived smooth muscle cells (SMCs) was tested in two in-vivo experiments. In the first one, matrigel plugs containing hESC-derived SMCs, were transplanted in a NOD-SCID mouse dorsal skin fold angiogenesis model. In the second experiment, cells were subcutaneously injected into the hind limb of NOD-SCID mice. In both cases, the cells integrated into the vascular network of the host animal model. Differentiation into cardiogenic progenitor cells is achieved by treating the 8 day EB suspension culture with Dkk1, bFGF, and VEGF for 6 days. The resulting cells express cardiovascular-specific markers.
28 days
See additional Protocols for: Smooth Muscle
Generation of vascular smooth muscle cells from human embryonic stem cells